郑博,王新刚,龚艳君,李建平,陈明,霍勇,洪涛

• 1:北京大学第一医院心内科

摘要(Abstract)：

目的了解直接PCI术前负荷剂量阿托伐他汀治疗对ST段抬高型心肌梗死患者冠脉血流灌注、短期心血管不良事件以及安全性的影响。方法入选2010年1月至2011年3月在北京大学第一医院就诊且既往未服用他汀类药物的ST段抬高型心肌梗死患者83例,根据是否于直接PCI术前应用负荷剂量阿托伐他汀治疗分为强化组(阿托伐他汀80mg,41例)和对照组(无他汀预处理,42例),术后均接受阿托伐他汀20mg,1次/天治疗。主要终点为术后即刻TIMI血流分级、校正的TIMI血流帧数、TIMI心肌灌注分级。次要终点为术后30天的心血管死亡、非致死性心肌梗死和靶血管血运重建的复合终点。安全性终点为出院前肝酶、肌酸激酶以及肾功能水平。结果强化组相比对照组术后即刻TIMI3级血流比例显著增加(87.8%比64.3%,χ2=6.28,P=0.02),校正的TIMI血流帧数明显减低(21.72±9.42比32.64±15.51,t=-3.87,P<0.001),而强化组TIMI心肌灌注分级亦明显高于对照组(2.71±0.64比2.15±0.74,t=3.68,P<0.001)。次要终点中,强化组和对照组分别有4.9%和4.8%出现主要心血管不良事件(χ2=0.001,P=0.926)。出院前两组丙氨酸氨基转移酶、肌酸激酶以及肌酐水平差异无统计学意义。多因素分析显示,在校正年龄、性别、吸烟、糖尿病、血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂、后扩张、血栓抽吸术等因素后,术前应用阿托伐他汀80mg负荷剂量仍为避免出现慢血流/无复流的独立预测因素(OR=0.22,95%CI0.06～0.87,P=0.03)。结论强化阿托伐他汀负荷剂量可以改善ST段抬高型心肌梗死患者直接PCI术后的冠状动脉血流及心肌灌注,并且不增加不良反应的发生率。

关键词(KeyWords)： 心肌梗死;阿托伐他汀;血管成形术,经腔,经皮冠状动脉;冠状动脉循环

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 郑博,王新刚,龚艳君,李建平,陈明,霍勇,洪涛

参考文献(References)：

• [1]Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC),Steg PG,James SK,Atar D,et al.ESC Guidelines for the management of acutemyocardial infarction in patients presentingwith ST-segment elevation.Eur Heart J,2012,33:2569-2619.
• [2]Laster SB,O'Keefe JH Jr,Gibbons RJ et al.Incidence and importance of thrombolysis in myocardial infarction grade3flow after primary percutaneous transluminal coronary angioplasty for acute myocardialinfarction.Am J Cardiol,1996,78:623-626.
• [3]Ndrepepa G,Tiroch K,Fusaro M,et al.5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction.J Am Coll Cardiol,2010,55:2383-2389.
• [4]Svilaas T,Vlaar PJ,van der Horst IC,et al.Thrombus aspiration during primary percutaneous coronary intervention.N Engl J Med,2008,358:557-567.
• [5]Vlaar PJ,Svilaas T,van der Horst IC,et al.Cardiac death and reinfarction after1year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study(TAPAS):a1-year follow-up study.Lancet,2008,371:1915-1920.
• [6]Burzotta F,De Vita M,Gu YL,et al.Clinical impact of thrombectomy in acute ST-elevation myocardial infarction:meta-analysis of randomized trials.Eur Heart J,2008,29:2989-3001.
• [7]Fokkema ML,Vlaar PJ,Svilaas T,et al.Incidence and clinical consequences of distal embolization the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction.Eur Heart J,2009,30:908-915.
• [8]Pasceri V,Patti G,Nusca A,et al.Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention:results from the ARMYDA(Atorvastatin for Reduction of MYocardial Damage during Angioplasty)study.Circulation,2004,110:674-678.
• [9]Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDA-ACS randomized trial.J Am Coll Cardiol,2007,49:1272-1278.
• [10]Chang SM,Yazbek N,Lakkis NM.Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome.Catheter Cardiovasc Interv,2004,62:193-197.
• [11]Celik T,Kursaklioglu H,Iyisoy A,et al.The effects of prior use ofatorvastatin on coronary blood flow after primary percutaneous coronaryintervention in patients presenting with acute myocardial infarction.Coron Artery Dis,2005,16:321-326.
• [12]Lev EI,Kornowski R,Vaknin-Assa H,et al.Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.Am J Cardiol,2009,103:165-169.
• [13]Kim JS,Kim J,Choi D,et al.Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction:the STATIN STEMI trial.JACC Cardiovasc Interv,2010,3:332-339.
• [14]Van't Hof AW,Liem A,Suryapranata H,et al.Angiographic assessment of myocardial reperfusion inpatients treated with primary angioplasty for acute myocardial infarction:myocardial blush grade.Zwolle Myocardial Infarction Study Group.Circulation,1998,97:2302-2306.
• [15]The Thrombolysis in Myocardial Infarction(TIMI)trial.Phase I findings.TIMI Study Group.N Engl J Med,1985,312:932-936.
• [16]Gibson CM,Cannon CP,Daley WL,et al.TIMI frame count:a quantitative method of assessing coronary artery flow.Circulation,1996,93:879-888.
• [17]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial.JAMA,2001,285:1711-1718.
• [18]Shepherd J,Cobbe SM,Ford I,et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.West of Scotland Coronary Prevention Study Group.N Engl J Med,1995,333:1301-1307.
• [19]LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med,2005,352:1425-1435.
• [20]Chua SK,Hung HF,Cheng JJ,et al.Incidence,predictors and outcomes of subacute stent thrombosis following primary stenting for ST-elevation myocardial infarction.J Formos Med Assoc,2010,109:430-437.
• [21]Cannon CP,Braunwald E,McCabe CH,et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med,2004,350:1495-1504.
• [22]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial.JAMA,2001,285:1711-1718.
• [23]Hinoi T,Matsuo S,Tadehara F,et al.Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography.Am J Cardiol,2005,96:89-91.
• [24]Bell RM,Yellon DM.Atorvastatin,administered at the onset of reperfusion,and independent of lipid lowering,protects the myocardium by up-regulating a pro-survival pathway.J Am Coll Cardiol,2003,41:508-515.